Table 3.
Multivariate analysis of variables for the prediction of survival outcomes in training cohort.
| Variables | Overall survival | Cancer-specific survival | Metastasis-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | |
| Age (>65 vs. ≤65 years) | 2.119 | 1.234–3.636 | 0.006* | 1.746 | 0.941–3.240 | 0.077 | 1.521 | 0.932–2.482 | 0.094 |
| BMI (≥25 vs. <25) | 0.795 | 0.367–1.726 | 0.562 | 0.948 | 0.388–2.314 | 0.907 | 0.578 | 0.284–1.173 | 0.129 |
| ASA grade (≥3 vs. <3) | 1.593 | 0.916–2.769 | 0.099 | – | – | ||||
| Hydronephrosis (Yes vs. No) | 2.009 | 1.204–3.353 | 0.008* | 1.940 | 0.958–3.928 | 0.066 | 1.855 | 1.059–3.248 | 0.031* |
| SIRI (≥1.36 vs. <1.36) | 2.005 | 1.103–3.644 | 0.022* | 2.271 | 1.146–4.500 | 0.019* | 2.257 | 1.277–3.987 | 0.005* |
| NLR (≥2.53 vs. <2.53) | 0.855 | 0.435–1.683 | 0.651 | 0.687 | 0.314–1.504 | 0.348 | 0.459 | 0.240–0.876 | 0.118 |
| PLR (≥126.88 vs. <126.88) | 1.786 | 1.020–3.128 | 0.043* | 1.650 | 0.867–3.142 | 0.127 | 1.333 | 0.791–2.247 | 0.280 |
| MLR (≥0.35 vs. <0.35) | 0.708 | 0.408–1.229 | 0.220 | 0.759 | 0.402–1.432 | 0.395 | 0.901 | 0.525–1.548 | 0.706 |
| Anemia (Yes vs. No) | 0.979 | 0.585–1.638 | 0.934 | 0.923 | 0.499–1.709 | 0.799 | 1.314 | 0.816–2.116 | 0.261 |
| Hypoproteinemia (Yes vs. No) | 0.785 | 0.374–1.646 | 0.522 | 0.878 | 0.380–2.025 | 0.760 | 0.784 | 0.370–1.660 | 0.525 |
| CKD stage | |||||||||
| CKD 1 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 |
| CKD 2–3 | 1.372 | 0.464–4.052 | 0.567 | 1.323 | 0.377–4.644 | 0.662 | 1.025 | 0.383–2.743 | 0.961 |
| CKD 4–5 | 1.284 | 0.372–4.431 | 0.693 | 1.357 | 0.322–5.723 | 0.678 | 1.300 | 0.399–4.235 | 0.663 |
| Tumor size (≥3 vs. <3) | 1.682 | 1.060–2.669 | 0.027* | 2.010 | 1.168–3.460 | 0.012* | 1.526 | 0.992–2.348 | 0.055 |
| Tumor site | |||||||||
| Pelvicalyceal | – | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | ||
| Ureter | 1.928 | 1.032–3.603 | 0.040* | 1.656 | 0.982–2.794 | 0.059 | |||
| Both | 1.914 | 0.646–5.674 | 0.242 | 1.508 | 0.633–3.591 | 0.354 | |||
| Multifocality (Yes vs. No) | 1.043 | 0.600–1.813 | 0.880 | 1.236 | 0.668–2.287 | 0.500 | – | ||
| Pathologic T stage | |||||||||
| pT1 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 |
| pT2 vs. pT1 | 1.313 | 0.649–2.655 | 0.449 | 1.795 | 0.699–4.609 | 0.224 | 1.837 | 0.963–3.503 | 0.065 |
| pT3 vs. pT1 | 2.812 | 1.394–5.675 | 0.004* | 4.202 | 1.658–10.651 | 0.002* | 2.181 | 1.089–4.368 | 0.028* |
| pT4 vs. pT1 | 6.586 | 1.536–28.239 | 0.011* | 17.249 | 3.435–86.610 | 0.001* | 6.585 | 1.590–27.267 | 0.009* |
| N stage (N1 vs. N0) | 1.215 | 0.239–6.189 | 0.014* | 1.518 | 1.098–2.732 | 0.038* | 1.124 | 0.219–5.761 | 0.888 |
| Tumor grade (≥3 vs. <3) | 1.370 | 0.626–2.997 | 0.430 | 2.216 | 0.750–6.547 | 0.150 | 1.484 | 0.773–2.850 | 0.235 |
| LVI (Yes vs. No) | 1.730 | 0.776–3.856 | 0.180 | 2.831 | 1.179–6.793 | 0.020* | 1.281 | 0.560–2.931 | 0.558 |
| Adjuvant therapy (Yes vs. No) | 1.905 | 1.114–3.257 | 0.019* | 2.161 | 1.222–3.820 | 0.008* | 2.345 | 1.402–3.924 | 0.001* |
*
Statistically significant.